Cancer and tobacco control training and research across the lifespan in Kenya

肯尼亚整个生命周期的癌症和烟草控制培训和研究

基本信息

  • 批准号:
    8531371
  • 负责人:
  • 金额:
    $ 20.31万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-10 至 2016-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The burden of cancer and tobacco consumption are major causes of morbidity and mortality in Kenya, a country with limited research infrastructure and significant scarcity to address these ever increasing chronic, non- communicable disease (NCD) threats to public health. Building on a near 15-year long research collaboration in Nairobi; a 20-year long academic partnership Academic Model Providing Access to Healthcare in Eldoret; capitalizing on a current NCI D43 training grant devoted to AIDS malignancy that is building critical pathology, tumor virology and clinical trials capacity; other NCI and CDC-funded research projects; an international team of highly interactive and experienced investigators led by Drs. Scot Remick, West Virginia University (WVU) and his senior Kenyan collaborator Walter Mwanda, University of Nairobi (UoN); Dr. Geoffrey Mutuma at Kenya Medical Research Institute (KEMRI); Dr. Brigid Sirengo at Nairobi Hospice; Dr. Patrick Loehrer at Indiana University (IU) and his senior Kenyan collaborator Dr. Naftali Busakhala, Moi University (MU) are partnering to develop sustainable research capacity for cancer and tobacco control in Kenya across the lifespan. Our training program will link for the first time the 5 essential academic medical and research centers in Kenya: UoN College of Health Sciences and affiliated Kenyatta National Hospital (KNH) in Nairobi; KEMRI; and the MU College of Health Sciences and affiliated Moi Teaching and Referral Hospital (MTRH) in Eldoret. The overall goal of our D43 training program is to bridge existing research capacity in Kenya, enabling strategic and inclusive multidisciplinary teams that will provide a solid foundation for development and implementation of evidence-based interventions relevant to cancer and tobacco control that will translate into Kenyan public health policy. The essential objectives are to strengthen the infrastructure for cancer and tobacco control in Kenya such that by the end of the 5-year Fogarty award highly interactive teams of investigators and research personnel will: (1) register cancer and other NCD entities (e.g., cerebrovascular disease) in population-based registries to inform national health officials and research programs; (2) develop effective tobacco cessation and control strategies for community intervention(s) and further frame tobacco policy; (3) support pathology research projects for successful completion of the MMed(Pathology) degree program to develop the next generation of trained pathologists for cancer diagnosis and lead multidisciplinary tumor boards; and (4) build research capacity for end-of-life cancer care and generate effective evidence-based interventions especially for children with cancer. Common training themes include: (1) the bulk of the training will be on-site in Kenya, which allows us to provide direct training for more members of our health teams; (2) address both intellectual - "people" and technical - "laboratory" capacities; (3) provide a variety of short, medium and long-term, "south-to-south", and electronic/web-based training coursework taking advantage of a newly fit-up electronic conference room in the Department of Pathology at UoN; and (4) provide training for the responsible conduct of research, protections of human subjects, and scientific/grants writing that feeds into a pilot research awards mechanism.
描述(由申请人提供):癌症负担和烟草消费是肯尼亚发病率和死亡率的主要原因,肯尼亚的研究基础设施有限,严重缺乏应对这些日益严重的慢性非传染性疾病(NCD)对公共卫生的威胁。在内罗毕近15年的长期研究合作的基础上;在埃尔多雷特提供医疗保健机会的20年学术伙伴关系学术模式;利用目前NCI D43培训赠款专门用于艾滋病恶性肿瘤,正在建立关键病理学,肿瘤病毒学和临床试验能力;其他NCI和CDC资助的研究项目;由西弗吉尼亚大学(WVU)的Scot Remick博士和他的肯尼亚高级合作者内罗毕大学(UoN)的Walter Mwanda博士领导的高度互动和经验丰富的研究人员组成的国际团队;肯尼亚医学研究所(KEMRI)的Geoffrey Mutuma博士;内罗毕临终关怀中心的Brigid Sirengo博士、印第安纳州大学(IU)的帕特里克·勒勒博士和他的肯尼亚高级合作者莫伊大学(MU)的Naftali Busakhala博士正在合作开发肯尼亚癌症和烟草控制的可持续研究能力。我们的培训计划将首次连接肯尼亚的5个重要学术医疗和研究中心:内罗毕的UoN健康科学学院和附属肯雅塔国家医院(KNH); KEMRI;和MU健康科学学院和附属Moi教学和转诊医院(MTRH)在埃尔多雷特。我们的D43培训计划的总体目标是弥合肯尼亚现有的研究能力,使战略和包容性的多学科团队,将提供一个坚实的基础,为发展和实施相关的癌症和烟草控制,将转化为肯尼亚公共卫生政策的循证干预措施。基本目标是加强肯尼亚癌症和烟草控制的基础设施,以便在五年福格蒂奖结束时,高度互动的调查人员和研究人员团队将:(1)登记癌症和其他非传染性疾病实体(例如,(2)制定有效的戒烟和控制策略,以进行社区干预,并进一步制定烟草政策;(3)支持病理学研究项目,以成功完成MMed(病理学)学位课程,培养下一代训练有素的病理学家进行癌症诊断和领导多学科肿瘤委员会;(4)建立癌症临终关怀的研究能力,并制定有效的循证干预措施,特别是针对癌症儿童。常见的培训主题包括:(1)大部分培训将在肯尼亚现场进行,这使我们能够为我们卫生团队的更多成员提供直接培训;(2)解决知识-“人员”和技术-“实验室”能力问题;(3)提供各种短、中、长期的“南南合作”,和电子/网络为基础的培训课程,利用新装修的电子会议室在病理学系在纽约大学的优势;以及(4)为负责任地开展研究、保护人类受试者以及为试点研究奖励机制提供科学/赠款写作方面的培训。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scot C Remick其他文献

Drug Insight: vascular disrupting agents and angiogenesis—novel approaches for drug delivery
药物洞察:血管破坏剂与血管生成——药物递送的新方法
  • DOI:
    10.1038/ncponc0663
  • 发表时间:
    2006-12-01
  • 期刊:
  • 影响因子:
    82.200
  • 作者:
    Matthew M Cooney;Willem van Heeckeren;Shyam Bhakta;Jose Ortiz;Scot C Remick
  • 通讯作者:
    Scot C Remick

Scot C Remick的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scot C Remick', 18)}}的其他基金

A Period Seroprevalence (SARS-CoV-2) Survey in MHCCN Cancer Healthcare Workers (HCWs) Providing Patient Care during the Height of the Outbreak: A Registry Study
对在疫情高峰期提供患者护理的 MHCCN 癌症医护人员 (HCW) 进行的期间血清阳性率 (SARS-CoV-2) 调查:登记研究
  • 批准号:
    10166146
  • 财政年份:
    2019
  • 资助金额:
    $ 20.31万
  • 项目类别:
Cancer and tobacco control training and research across the lifespan in Kenya
肯尼亚整个生命周期的癌症和烟草控制培训和研究
  • 批准号:
    8337683
  • 财政年份:
    2012
  • 资助金额:
    $ 20.31万
  • 项目类别:
Cancer and tobacco control training and research across the lifespan in Kenya
肯尼亚整个生命周期的癌症和烟草控制培训和研究
  • 批准号:
    8652333
  • 财政年份:
    2012
  • 资助金额:
    $ 20.31万
  • 项目类别:
Developing Research Capacity for AIDS Malignancy in Kenya
发展肯尼亚艾滋病恶性肿瘤的研究能力
  • 批准号:
    8125006
  • 财政年份:
    2010
  • 资助金额:
    $ 20.31万
  • 项目类别:
Developing Research Capacity for AIDS Malignancy in Kenya
发展肯尼亚艾滋病恶性肿瘤的研究能力
  • 批准号:
    8698961
  • 财政年份:
    2010
  • 资助金额:
    $ 20.31万
  • 项目类别:
Developing Research Capacity for AIDS Malignancy in Kenya
发展肯尼亚艾滋病恶性肿瘤的研究能力
  • 批准号:
    8308611
  • 财政年份:
    2010
  • 资助金额:
    $ 20.31万
  • 项目类别:
Developing Research Capacity for AIDS Malignancy in Kenya
发展肯尼亚艾滋病恶性肿瘤的研究能力
  • 批准号:
    8009569
  • 财政年份:
    2010
  • 资助金额:
    $ 20.31万
  • 项目类别:
PS-341 IN PATIENTS WITH ADVANCED MALIGNANCIES AND RENAL DYSFUNCTION
PS-341 用于晚期恶性肿瘤和肾功能不全的患者
  • 批准号:
    7378050
  • 财政年份:
    2006
  • 资助金额:
    $ 20.31万
  • 项目类别:
17-ALLYLAMINO-17 DEMETHOXYGELDANAMYCIN (17-AAG) W/PACLITAXEL IN ADV SOLID TUMORS
17-烯丙氨基-17 去甲氧基格尔德霉素 (17-AAG) 联合紫杉醇治疗 ADV 实体瘤
  • 批准号:
    7378069
  • 财政年份:
    2006
  • 资助金额:
    $ 20.31万
  • 项目类别:
COMBRETASTATIN/DOXORUBICIN/CISPLATIN FOR PATIENTS WITH THYROID CANCER
康布他汀/阿霉素/顺铂用于甲状腺癌患者
  • 批准号:
    7378051
  • 财政年份:
    2006
  • 资助金额:
    $ 20.31万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.31万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了